Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with Levodopa

Authors:
  • DCD. B. Calne
    D. B. Calne
  • JRJ. L. Reid
    J. L. Reid
  • SVS. D. Vakil
    S. D. Vakil
  • SRSumant Rao
    Sumant Rao
  • APA. Petrie
    A. Petrie
  • CPC. A. Pallis
    C. A. Pallis
  • JGJ. Gawler
    J. Gawler
  • PTP. K. Thomas
    P. K. Thomas
  • AHA. Hilson
    A. Hilson

Abstract
The clinical actions of levodopa in Parkinsonism, given with and without an extracerebral decarboxylase in hibitor, L-alpha-methyldopahydrazine, were compared. Twenty-one patients were investigated in a “double-blind cross-over” study, administering levodopa in maximum tolerated dosage. L-Alpha-methyldopahydrazine failed to augment the overall therapeutic actions of levodopa but it consistently alleviated nausea. It is concluded that L-alpha-methyldopahydrazine will prove useful in the management of some Parkinsonian patients who have difficulty in taking levodopa alone.